Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.
Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.
Company Details
- Employees
- 9
- Founded
- 2018
- Address
- 200 Biddle Ave,
- Industry
- Biotechnology
- Website
- http://uvaxbio.com
- Keywords
- Philadelphia.
- HQ
- Newark, Delaware
Uvax Bio Questions
Uvax Bio's website is http://uvaxbio.com
Uvax Bio's LinkedIn profile is https://www.linkedin.com/company/uvax-bio
Uvax Bio has
9 employees.
View email and phone details for 9
employees at Uvax Bio.
Uvax Bio's industry is
Biotechnology
Uvax Bio's top competitors are
Geovax Labs, Inc.,
Uvax,
Exuma Biotech,
Gritstone Bio,
Vertex Pharmaceuticals,
Neumora,
Biotherapeutics Inc.,
Fruitist,
Monell Chemical Senses Center,
Vivaldi Biosciences.
Uvax Bio's categories are Biotechnology
Uvax Bio's founding year is 2018
